An international forum where the latest gene and cell therapy developments are presented and critically discussed. ASGCT's annual meeting brings together more than 3,400 professionals including scientists, physicians, and patient advocates.
Join us at the following sessions, and learn about our technologies first-hand with Pall’s scientists and experts. Leverage their expertise.
1. Tools and Technology Forum
Tuesday, May 11, 2021
6:15 – 6:30p.m EST
Transient Transfection at Large-Scale for Clinical AAV9 Vector Manufacturing
Denis Kole, Senior Manager, Process Development Services SLS, Pall Corporation
2. Industry Symposium
Three case studies based on real-world experience
Considerations for upstream bioprocess development with a stirred tank bioreactor
Exosome manufacture in a fixed-bed bioreactor, and overcoming production challenges
Key benefits in having a technology partner in vector bioprocess scale-up
Wednesday May 12th
Moderator: Clive Glover, Director of Strategy, Cell and Gene Therapies, Pall Corporation
Allison DeGroat Daroszewski, Scientist, AAV Process Development, Abeona Therapeutics
Dr. David Haylock, CEO, VivaZome Therapeutics
Roberto Ciboldi, Senior Scientist, Pall Corporation
Jens Wölfel, Head of Downstream Processing and Analytics, Cevec Pharmaceuticals /Silke Wissing, Chief Scientific Officer, Cevec Pharmaceuticals
3. Posters sessions:
#125. High Titer rAAV Production upon Upstream Process Development of Stable Helper-Virus Free ELEVECTA® Producer Cells
#172. Use of SPTFF in Continuous Downstream Manufacturing of Adeno-Associate Viruses
#666. Development and Industrialization of a Cost-Effective Reproducible Oncolytic Virus Production Process Using the iCELLis® Bioreactor System
#807. Demonstration of Transient Transfection Scalability for a Suspension AAV9 Viral Vector Production Process up to 500 Liter Manufacturing Scale
#816. How to Mitigate Contamination Risk for Viral Vector Large Scale Production
#818. Empty and Full Separation of AdenoAssociated Virus Vectors by Anion Exchange Membrane Chromatography
#830. Comparative Analysis of Anion Exchange Chromatography for the Enrichment of Adeno-Associated Virus Serotype 9 Full Particles Using a Conductivity Step Gradient
#838. Efficient Lentiviral Vector Production in a Chemically Defined, Blood-Free and Serum-Free Medium, Scalable to the iCELLis® Technology
#842. Meeting Market Needs with Scalable AAV Manufacturing
#854. Scale up of a Lentiviral Production Process from the iCELLis® Nano Bioreactor to the iCELLis 500 + Bioreactor
#857. Application of Aber’s FUTURA♦ Biomass Probes to Inform Transfection and Cell Lysis in iCELLis® Bioreactor-Based AAV Manufacturing
Pall products featured:
iCELLis® single-use scalable bioreactors https://shop.pall.com/us/en/search?SearchTerm=icellis&resetsearch=true
Stax™ clarification technologies https://shop.pall.com/us/en/search?SearchTerm=Stax%E2%84%A2+clarification+technologies+&selectedtab=&resetsearch=true
Mustang® chromatography devices Cadence single-use / single-pass UF/DF https://shop.pall.com/us/en/search?SearchTerm=Mustang%C2%AE+chromatography+devices+Cadence+single-use+%2F+single-pass+UF%2FDF+&selectedtab=&resetsearch=true
Allegro™ buffer management systems https://shop.pall.com/us/en/search?SearchTerm=Allegro%E2%84%A2+buffer+management+systems+&selectedtab=&resetsearch=true
Pall Freeze and Go Solutions https://shop.pall.com/us/en/search?SearchTerm=Pall+Freeze+and+Go+Solutions&selectedtab=&resetsearch=true
Can’t wait for the event date to start? You may be interested in the following preview:
To learn more about Pall’s approach to clarification, download article here.
Master large-scale transfection. Listen to podcast and get your guide here.
To learn more about Pall’s approach to separation of empty and full AAV capsids, listen to podcast here.